Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART).

Mayor AM, Fernández Santos DM, Dworkin MS, Ríos-Olivares E, Hunter-Mellado RF.

Am J Trop Med Hyg. 2011 May;84(5):838-41. doi: 10.4269/ajtmh.2011.10-0718.

2.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.

Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare ER, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d'Arminio Monforte A; Italian Registry Investigative NeuroAIDS.

Clin Infect Dis. 2004 Dec 1;39(11):1681-91. Epub 2004 Nov 5.

3.

[Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

Pozio E.

Parassitologia. 2004 Jun;46(1-2):89-93. Review. Italian.

PMID:
15305694
4.

Changes in the AIDS epidemiologic situation in Puerto Rico following health care reform and the introduction of HAART.

Báez-Feliciano DV, Thomas JC, Gómez MA, Miranda S, Fernández DM, Velázquez M, Ríos-Olivares E, Hunter-Mellado RF.

Rev Panam Salud Publica. 2005 Feb;17(2):92-101.

PMID:
15826386
5.

Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.

Connolly MP, Goodwin E, Schey C, Zummo J.

Pathog Glob Health. 2017 Feb;111(1):31-44. doi: 10.1080/20477724.2016.1273597. Epub 2017 Jan 16. Review.

PMID:
28090819
6.

Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).

Kiderlen TR, Liesenfeld O, Schürmann D, Schneider T.

Eur J Clin Microbiol Infect Dis. 2011 Dec;30(12):1521-5. doi: 10.1007/s10096-011-1254-6. Epub 2011 Apr 15.

PMID:
21491176
7.

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.

Abgrall S, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Clin Infect Dis. 2001 Nov 15;33(10):1747-55. Epub 2001 Oct 10.

PMID:
11595976
8.
9.

[Ocular involvement in AIDS patients with central nervous system toxoplasmosis: before and after HAART].

Zajdenweber M, Muccioli C, Belfort R Jr.

Arq Bras Oftalmol. 2005 Nov-Dec;68(6):773-5. Portuguese.

10.

Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses.

Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, Stoehr A, Horst HA, Marienfeld K, Lange C.

Clin Microbiol Infect. 2007 May;13(5):510-5. Epub 2007 Feb 12.

11.

Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).

Dedicoat M, Livesley N.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005420. Review.

PMID:
16856096
12.

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B.

J Infect Dis. 2000 May;181(5):1635-42. Epub 2000 May 15.

PMID:
10823763
13.

[Clinical analysis of 16 AIDS patients complicated with toxoplasmic encephalitis].

Zhao JR, Zhang S, Du JP, Wang S, Wang DY.

Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2010 Jun 30;28(3):237-8. Chinese.

PMID:
20806515
14.

Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.

Zeller V, Truffot C, Agher R, Bossi P, Tubiana R, Caumes E, Jouan M, Bricaire F, Katlama C.

Clin Infect Dis. 2002 Mar 1;34(5):662-7. Epub 2002 Jan 24.

PMID:
11810599
15.

Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.

Schürmann D, Bergmann F, Albrecht H, Padberg J, Wünsche T, Grünewald T, Schürmann M, Grobusch M, Vallée M, Ruf B, Suttorp N.

Eur J Clin Microbiol Infect Dis. 2002 May;21(5):353-61. Epub 2002 May 18.

PMID:
12072919
17.

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

Ann Intern Med. 2001 Jul 3;135(1):17-26.

PMID:
11434728
18.

[Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].

Bossi P, Caumes E, Astagneau P, Li TS, Paris L, Mengual X, Katlama C, Bricaire F.

Rev Med Interne. 1998 May;19(5):313-7. French.

PMID:
9775164
19.

AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.

Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF.

Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-189-94.

Supplemental Content

Support Center